

# Preliminary Programme



**isirv**  
International Society for  
Influenza and other  
Respiratory Virus Diseases

## Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID Pandemic

**1 - 3 March 2023**    **Seattle | USA**

### Day 1    Wednesday 1 March

**08:00**    Registration / Poster Mounting

**09:00**    **Welcome and Opening Remarks**    **Ros Hollingsworth** Bill & Melinda Gates Foundation, USA

**Session A**    **Lessons Learned from the COVID Pandemic and New COVID Vaccine Platforms**  
**Chairs: Jackie Katz** The Taskforce for Global Health Inc., USA    **Joe Bresee** The Taskforce for Global Health Inc., USA

**09:05**    **Lessons Learned from New COVID Vaccines**  
**Sarah Gilbert** University of Oxford, UK

**09:35**    **Lessons Learned from the COVID Pandemic**  
**Florian Krammer** Icahn School of Medicine at Mount Sinai, USA

**09:55**    **What Can We Learn from the Human Challenge of SARS-CoV-2 and Flu?**  
**Chris Chiu** Imperial College London, UK

**10:20**    **Correlates of Protection**  
**Miles Davenport** Kirby Institute, UNSW Sydney, Australia

<b>10:40</b>	<b>BREAK</b>
<b>Session B</b>	<p><b>Next Generation/Universal Influenza Vaccine</b>  <b>Chairs:</b> <b>Othmar Engelhardt</b> NIBSC, UK <b>Kanta Subbarao</b> WHO Collaborating Centre, University of Melbourne, Australia</p>
<b>11:10</b>	<p><b>Universal Influenza Vaccine</b>  <b>Florian Krammer</b> Icahn School of Medicine at Mount Sinai, USA</p>
<b>11:40</b>	<p><b>Next Generation Influenza Vaccines</b>  <b>Aaron Schmidt</b> Harvard Medical School; Ragon Institute of MGH, MIT and Harvard, USA</p>
<b>12:00</b>	<p><b>Correlates of Protection from Cohort Studies to Guide Next Generation Influenza Vaccine</b>  <b>Aubree Gordon</b> University of Michigan, USA</p>
<b>12:20</b>	<p><b>Correlates of Protection for Next Generation/Universal Influenza Vaccine</b>  <b>Arnold Monto</b> University of Michigan, USA</p>
<b>12:40</b>	<b>LUNCH</b>
<b>Session C</b>	<p><b>Immunology B and T Cell Update</b>  <b>Chairs:</b> <b>Florian Krammer</b> Icahn School of Medicine at Mount Sinai, USA <b>Diane Post</b> NIH, USA</p>
<b>14:00</b>	<p><b>Role of T Cells in Vaccine Responses</b>  <b>Shane Crotty</b> La Jolla Institute for Immunology, CA, USA</p>
<b>14:30</b>	<p><b>B Cells After Influenza Vaccination</b>  <b>Ali Ellebedy</b> Washington University School of Medicine, St Louis, USA</p>
<b>15:00</b>	<p><b>CD8 T Cells in Protection from Influenza</b>  <b>Paul Thomas</b> St. Jude Children's Research Hospital, USA</p>
<b>15:30</b>	<p><b>Role of Non HI Antibodies in Protection from Influenza</b>  <b>Galit Alter</b> Massachusetts General Hospital, Boston, MA, USA</p>

<b>16:00</b>	<b>BREAK</b>
<b>Session D</b>	<b>Mucosal Correlates of Immunity and Protection</b> <b>Chairs:</b> <b>Ali Ellebedy</b> Washington University School of Medicine, St Louis, USA <b>Ros Hollingsworth</b> Bill & Melinda Gates Foundation, USA
<b>16:30</b>	<b>Mucosal Correlates of Immunity and Protection</b> <b>Peter Openshaw</b> Imperial College London, UK
<b>17:00</b>	<b>Mucosal Data from LAIV</b> <b>Kanta Subbarao</b> WHO Collaborating Centre, University of Melbourne, Australia
<b>17:30</b>	<b>The Role of Mucosal Immunity to Influenza</b> <b>Stacey Schultz-Cherry</b> St Jude Children’s Research Hospital, USA
<b>17:50</b>	<b>Local Immunity After Influenza Vaccination</b> <b>Rebecca Cox</b> , University of Bergen, Norway
<b>18:10</b>	<b>The Role of Local Antibodies in SARS CoV-2 Protection</b> <b>Jennifer Gommerman</b> University of Toronto, Canada
<b>18:10</b>	<b>EVENING RECEPTION and POSTER SESSION</b>

# Day 2 Thursday 2 March

## Session E

### Immunological Assays

**Chairs:** **Rebecca Cox** University of Bergen, Norway **Paul Thomas** St Jude Children's Research Hospital, USA

09:00

#### Lessons Learned from the HIV Network

Adrian McDermot

09:30

#### Lessons Learned from SARS CoV-2 Assays

David Montefiori (remote)

#### Lessons Learned from FLUCOP

09:45

**HA Assays** **Othmar Engelhardt** National Institute for Biological Standards and Control, UK

10:05

**NA Assays** **Emanuele Montomoli** University of Siena, Italy

10:20

**T Cell Assays** **Gwenn Waerlop** Ghent University, Belgium

10:40

**BREAK**

## Session F

### Regulatory Session (hybrid)

**Chairs:** **Jerry Weir** FDA, USA **Chris Roberts** NIH, USA

11:10

#### Regulatory Hurdles for Next Generation Influenza Vaccines

**David Vaughn** Bill & Melinda Gates Foundation

11:40

#### PANEL DISCUSSION

#### How Can COP Help the Regulatory Process for Licensure of New Vaccines

**Sarah Gilbert** University of Oxford, UK

**Chris Chiu** Imperial College London, UK

**Jerry Weir** FDA, USA

**Marco Caveleri** EMA, The Netherlands

<b>12:30</b>	<b>LUNCH</b>
<b>Session G</b>	<b>Epidemiology, Statistics and Data Science</b> <b>Chairs:</b> <b>Joe Bresee</b> The Taskforce for Global Health Inc., USA <b>Sheena Sullivan</b> WHO Collaborating Centre for Reference and Research on Influenza, Peter Docherty Institute, Australia
<b>13:45</b>	<b>Influenza Vaccine Effectiveness</b> <b>Sheena Sullivan</b> WHO Collaborating Centre for Reference and Research on Influenza, Peter Docherty Institute, Australia
<b>14:15</b>	<b>Novel Study Design to Support Correlates of Protection Studies</b> <b>Peter B. Gilbert</b> University of Washington, USA
<b>14:45</b>	<b>Mathematical Modelling of Correlates of Protection</b> <b>Miles Davenport</b> Kirby Institute, UNSW Sydney, Australia
<b>15:05</b>	<b>PANEL DISCUSSION – Study Design for Correlates of Protection</b> <b>Aubree Gordon</b> University of Michigan, USA <b>Miles Davenport</b> Kirby Institute, UNSW Sydney, Australia <b>Sheena Sullivan</b> WHO Collaborating Centre for Reference and Research on Influenza, Peter Docherty Institute, Australia <b>Peter B. Gilbert</b> University of Washington, USA
<b>16:00</b>	<b>BREAK</b>
<b>Session H</b> <b>16:30 -18:00</b>	<b>Oral Abstracts</b> <b>Chairs:</b> <b>Mark Tompkins</b> University of Georgia, USA <b>Emanuele Montomoli</b> University of Siena, Italy
<b>19:30</b>	<b>SOCIAL EVENING</b>

# DAY 3 Friday 3 March

## Session I

09:00 – 11:00

### Oral Abstracts

**Chairs:** **Chris Chiu** Imperial College London, UK **Stacey Schultz-Cherry** St Jude Children's Research Hospital, USA

11:00

### BREAK

## Session J

11:30

### Recap of Sessions A-C

#### Group Discussion –

#### Lessons Learned from COVID for Identifying Correlates of Protection and Develop Consensus on Immune Responses to Target

**Florian Krammer** Icahn School of Medicine at Mount Sinai, USA

**Ali Ellebedy** Washington University School of Medicine, St Louis, USA

**Sarah Gilbert** University of Oxford, UK

**Kanta Subbarao** WHO Collaborating Centre, University of Melbourne, Australia

12:30

### LUNCH

## Session K

13:45

### Recap of Sessions D-F Group Discussion

#### The Way Forward in Correlates of Protection and their Detection for Next Generation Vaccines.

#### What are Relevant Immune Responses? | Best Assays Available | Approaches to Standardisation and Harmonisation

**Othmar Engelhardt** National Institute for Biological Standards and Control, UK

**Jerry Weir** FDA, USA

**Rebecca Cox** University of Bergen, Norway

**Jackie Katz** The Taskforce for Global Health Inc., USA

15:30	VISIT DISCOVERY CENTRE
16:30	<b>Closing Remarks – End of Meeting</b> <b>Ros Hollingsworth</b> Bill & Melinda Gates Foundation